HCA
RNAM

Harbor Capital Advisors’s Avidity Biosciences RNAM Stock Holding History

Harbor Capital Advisors’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,532
Closed -$615K – 1447
2025
Q4 		$615K Buy
+8,532
New +$551K 0.05% 424
2024
Q2 		– Sell
-40,068
Closed -$1.02M – 762
2024
Q1 		$1.02M Buy
40,068
+7,718
+24% +$121K 0.13% 207
2023
Q4 		$293K Buy
32,350
+2,336
+8% +$15.6K 0.06% 318
2023
Q3 		$191K Buy
30,014
+4,902
+20% +$42.2K 0.04% 355
2023
Q2 		$278K Buy
25,112
+2,296
+10% +$28.8K 0.06% 328
2023
Q1 		$350K Sell
22,816
-18,587
-45% -$409K 0.1% 167
2022
Q4 		$919K Sell
41,403
-891
-2% -$13.3K 0.89% 40
2022
Q3 		$691K Sell
42,294
-4,648
-10% -$88.9K 0.63% 52
2022
Q2 		$682K Buy
46,942
+1,503
+3% +$22.4K 0.52% 62
2022
Q1 		$839K Sell
45,439
-11,209
-20% -$190K 0.4% 69
2021
Q4 		$1.35M Buy
+56,648
New +$1.35M 0.49% 60

Other funds holding RNAM

CC
Corsicana & Co Corsicana, Texas $158M AUM

Harbor Capital Advisors's RNAM Position: Q1 2026 in Review

Harbor Capital Advisors sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 8,532 shares — an estimated $615K sold.

Harbor Capital Advisors first reported a position in RNAM in Q4 2021 and held it in 11 quarters. The position peaked at $1.35M in Q4 2021. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • Harbor Capital Advisors reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • Harbor Capital Advisors sold 8,532 Avidity Biosciences shares in Q1 2026, an estimated $615K.
  • Harbor Capital Advisors first reported a position in Avidity Biosciences in Q4 2021 and held it in 11 quarters.
  • Harbor Capital Advisors's Avidity Biosciences position peaked at $1.35M in Q4 2021.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Harbor Capital Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.